Phaseline

Companies › SPH-BIOCAD (HK)

SPH-BIOCAD (HK): clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Other; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
BCD-261
anti-TL1A human monoclonal antibody
TL1APhase 1Healthy Adult ParticipantsMar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07535775BCD-261Phase 1Healthy Adult ParticipantsOtherMar 2027

Targets

TL1A (1)

Companies with the same targets

Biocad Merck & Co. (MSD)

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.